Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes (Q40617990)

From Wikidata

Jump to navigation Jump to search

scientific article published on December 1, 2003

Language	Label	Description	Also known as
English	Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes	scientific article published on December 1, 2003

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

author name string

Tomoyuki Nishimoto

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Ryuichi Tozawa

2

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Yuichiro Amano

3

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Takeo Wada

4

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Yoshimi Imura

5

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Yasuo Sugiyama

6

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

language of work or name

0 references

publication date

1 December 2003

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0006295203006312?httpAccept=text/xml

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

https://api.elsevier.com/content/article/PII:S0006295203006312?httpAccept=text/plain

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Biochemical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

66

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

2133-2139

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin

1

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

2

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

3

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

HMG-CoA reductase inhibitors and myotoxicity

4

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro

6

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture

7

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

FDA adverse event reports on statin-associated rhabdomyolysis

8

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

9

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Drug treatment of lipid disorders

10

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins

11

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Cerivastatin and reports of fatal rhabdomyolysis

12

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis

13

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro

14

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia

15

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein

16

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis

17

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Merosin and laminin in myogenesis; specific requirement for merosin in myotube stability and survival

18

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture

23

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis

24

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study.

25

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans

26

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle

27

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Lovastatin increases exercise-induced skeletal muscle injury

29

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy

30

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

31

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Rhabdomyolysis: a review of the literature

32

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Myopathy and rhabdomyolysis with lipid-lowering drugs

33

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells

34

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Squalene synthase inhibition alters metabolism of nonsterols in rat liver

35

1 reference

10.1016/J.BCP.2003.08.011

https://api.crossref.org/works/10.1016/J.BCP.2003.08.011

31 March 2024

Identifiers

10.1016/J.BCP.2003.08.011

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40617990&oldid=2114959052"